Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Q3 2022 Earnings Call Transcript

David Benedicto: With regards for Braun, we have received all of the expected revenue from the sale of certain assets to them. What remains are the expected proceeds from the sale of the building, land and the remaining manufacturing equipment, which we expect could range from $3 million to $4 million. Thank you.

Robert Uhl: Okay. Great. And then here’s one more. Assuming the strategic process currently underway results in a definitive agreement, will it require shareholder approval, a shareholder vote?

David Marguglio: Yes. So I guess the answer depends on the outcome of that process and frankly, the nature of the agreement, that is the result. If the transaction that requires shareholder approval, then absolutely, we will be putting together a proxy and soliciting — describing the transaction and soliciting shareholder approval. And we would expect that process to begin right on the heels of signing any sort of definitive agreement.

Robert Uhl: Okay. Great. That — okay, we’ve come to the end of the questions that have been submitted to me. So at this time, I’d like to thank everyone for listening to our call and for your interest in Adamis Pharmaceuticals and thanks to the management team for their discussion of where they think they’re headed and for the good financial reporting that they have put out now for the third quarter. So thanks, everyone. And if you have additional questions, please contact us. All right. Thanks, everyone. Have a good evening.

Operator: Ladies and gentlemen, this concludes your conference call for today. We thank you for joining and ask that you please disconnect your lines. Thank you.